ARQT
Arcutis Biotherapeutics, Inc.
Key Financials
Revenue
$376.1M
↑ 91.3%
Operating Income
$-12227000
↑ 90.5%
Net Income
$-16141000
↑ 88.5%
Total Assets
$433.0M
↑ 24.1%
EPS (Diluted)
$-0.13
↑ 88.8%
Shareholders' Equity
$189.5M
↑ 20.3%
Cash & Equivalents
$42.9M
↓ 39.9%
Total Liabilities
$243.5M
↑ 27.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/3/2026 | View on SEC |
| 144 | 4/1/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/4/2026 | View on SEC |
| 4 | 3/4/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ARQT |
| Company Name | Arcutis Biotherapeutics, Inc. |
| CIK | 1787306 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 805-418-5006 |